source of intraperitoneal vascular endothelial growth factor (VEGF) and by that are presumably involved in complications of long-term peritoneal dialysis (PD), such as ultrafiltration failure. This prompted us to look for agents that reduce basic mesothelial VEGF production and abrogate VEGF-overproduction induced by proinflammatory cytokines such as tumor necrosis factor alpha (TNF-αα αα α) and interleukin-1αα αα α (IL-1αα αα α). Angiotensin-converting enzyme (ACE) inhibition was found to preserve peritoneal function and ameliorate morphologic changes in a rat PD model. The present in vitro study was designed to investigate the effect of the ACE inhibitors captopril and enalapril, and the angiotensin II type 1-receptor (AT1) antagonist losartan on mesothelial VEGF synthesis. ♦♦ ♦♦ ♦ Methods: HMC were isolated from omental tissue and taken into culture. VEGF antigen concentrations were measured in the cell supernatant by ELISA. VEGF mRNA levels were determined by real-time polymerase chain reaction. ing the overproduction of VEGF due to proinflammatory cytokine stimuli. These data suggest that locally produced angiotensin II in the peritoneal cavity may be a potential therapeutic target in ultrafiltration failure during longterm PD. I t has been shown previously that human mesothelial cells (HMC) are a major source of intraperitoneally produced vascular endothelial growth factor (VEGF) (1) . During peritoneal dialysis (PD), VEGF is supposed to play an important role in the modification of peritoneal membrane characteristics by increasing vascular permeability (2), inducing vasodilatation via stimulation of nitric oxide synthase (3), and stimulating angiogenesis (4). The VEGF expression in HMC can be upregulated by proinflammatory cytokines such as interleukin-1α (IL-1α) and tumor necrosis factor alpha (TNF-α), by thrombin, and by nonenzymatic glycation products, such as glycated albumin, which occur under treatment with PD fluids containing high concentrations of glucose (1) .
In a PD rat model using hypertonic dialysis solutions, enalapril was able to preserve peritoneal function and maintain mesothelial cell regeneration and remodeling (5) . Applied locally in a rat PD model, it was able to preserve ultrafiltration and thickening of the peritoneal membrane following treatment with hypertonic PD solutions (6) . Human mesothelial cells constitutively express all the components of a local renin-angiotensin system (RAS) (7) and show angiotensin-converting enzyme (ACE) activity similar to human endothelial cells (8) . Therefore, the objective of this in vitro study was to examine the effects of ACE-inhibiting and angiotensin II-receptor 1 (AT1) blocking agents on mesothelial basal and cytokine-stimulated VEGF production.
MATERIALS AND METHODS
Medium M199 and newborn calf serum were obtained from Gibco BRL (Eggenstein, Germany); tissue-culture plates came from Costar (Cambridge, Massachusetts, USA). Human serum was prepared from freshly collected blood of healthy donors and stored at -20°C. Fibronectin from human serum, trypsin, IL-1α, and TNF-α were purchased from Boehringer (Mannheim, Germany), and collagenase type II from Worthington (Freehold, New York, USA).
Monoclonal antibodies against cytokeratins 8 and 18 as well as vimentin were a gift from Dr. G. van Muijen (University of Nijmegen, The Netherlands). Captopril, enalapril, and MTT were from Sigma-Aldrich (Munich, Germany). Losartan was a generous gift from MSD.
CELL CULTURE EXPERIMENTS
Human mesothelial cells were isolated from the omental tissue of consenting patients undergoing elective surgery, as described previously (9) . Cells were grown in fibronectin-coated dishes in M199 medium supplemented with 25 mmol/L HEPES (pH 7.3), 2 mmol/L glutamine, 10% (v/v) human serum, 10% (v/v) newborn calf serum (heat inactivated), penicillin (100 IU/mL), and streptomycin (100 µg/mL) at 37°C under 5% CO 2 / 95% air atmosphere. The medium was replaced every 2 -3 days. Subcultures were obtained by trypsin/EDTA treatment at a split ratio of 1:3. The cells were purely HMC, as assessed by their uniform cobblestone appearance at confluence, by the absence of von Willebrand factor, and by their uniform positive staining for cytokeratins 8 and 18 as well as for vimentin. For the experiments, confluent cultures were used at the second or third passage and cells were re-fed with 2% human serum 24 hours before the experiment. Conditioned media were obtained by incubating cells in 2-cm 2 dishes at 37°C with 0.5 mL serum-free M199 containing the appropriate concentration of the test compound or stock solvent. Serum-free medium M199 served as a control. In co-incubation experiments, cells were preincubated for 2 hours with captopril, enalapril, or losartan and then the particular inflammatory mediators [TNF-α (1000 U/mL) or IL-1α (10 U/mL)] were added. Conditioned media were centrifuged 5 minutes at 2000g to remove cells and cellular debris, and the samples were frozen at -20°C until use. All experiments were done with cells from 3 -6 individual donors and were measured in triplicate.
ASSAY
Antigen levels of VEGF (pg/10 5 cells) were measured using Quantikine human VEGF immunoassay from R&D Systems (Minneapolis, Minnesota, USA). This assay recognizes the soluble isoforms VEGF 121 and VEGF 165 . Diluted aliquots of the cell supernatants were assayed without prior purification.
RNA ISOLATION AND REAL-TIME QUANTITATIVE REVERSE TRANSCRIPTION-POLYMERASE CHAIN REACTION (RT-PCR)
Total RNA was extracted from cells using silica gel columns (RNeasy; Qiagen, Hilden, Germany). RNA samples underwent random hexamer-primed reverse transcription for 1 hour at 40°C using a modified Moloney-murine leukemia virus (MMLV) reverse transcriptase (Superscript; Life Technologies, Karlsruhe, Germany). Real-time quantitative RT-PCR was performed on a Taq-Man ABI 7700 Sequence Detection System (PE Biosystems, Weiterstadt, Germany) using heat-activated TaqDNA polymerase (Amplitaq Gold; Applied Biosystems, Darmstadt, Germany). Thermal cycler conditions contained holds for 2 minutes at 50°C and 10 minutes at 95°C, followed by 40 cycles of 15 seconds at 95°C and 1 minute at 60°C. Message expression was calculated following the ddCt procedure (10). Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and ribosomal RNA (rRNA) served as the reference housekeeping gene. Controls consisting of H 2 O or samples that were not reverse transcribed were negative for the target and reference.
The following oligonucleotide primers (300 nmol/L) and probe (100 nmol/L) were used for human VEGF (gb NM-003376; bp 53-127): sense, 5'-GCCTTGCTG-CTCTACCTCCAC-3', antisense, 5'ATGATTCTGCCCTCCTCCT-TCT-3'; internal fluorescence-labeled probe (FAM), 5'AAGTGGTCCCAGGCTGCACCCAT-3', detecting all known VEGF isoforms. Commercially available, predeveloped TaqMan reagents were used for GAPDH and rRNA. Primers and probes were obtained from Applied Biosystems.
STATISTICAL ANALYSIS
Data are given as mean ± SD. Statistical analysis was performed using ANOVA. A p value < 0.05 was considered indicative of a statistically significant difference. 
RESULTS

EFFECTS OF CAPTOPRIL, ENALAPRIL, AND LOSARTAN ON THE PRODUCTION OF VEGF IN HMC
Confluent HMC were incubated with increasing concentrations of captopril (100 -1000 µmol/L), enalapril (10 -1000 µmol/L), and losartan (1 -100 µmol/L) for 48 hours. The addition of captopril resulted in a concentration-dependent decrease in VEGF antigen levels in the cell culture supernatant. Captopril treatment reached statistical significance at a concentration of 500 µmol/L (p = 0.001) with 1327 pg/10 5 cells (vs control 2130 pg/10 5 cells), and was intensified at a concentration of 1000 µmol/L (870 pg/10 5 cells) (Figure 1) . Furthermore, captopril decreased VEGF synthesis in a time-dependent manner, being statistically significant at all points of measurement (8, 24, 48 , 72 hours) (data not shown), and did not affect cell viability as assessed in trypan blue staining and MTT assay (Figure 2 ). The incubation with different concentrations of enalapril (10 -1000 µmol/L) and losartan did not result in signif icant alterations of mesothelial VEGF levels ( Figure 1 ).
EFFECT OF CAPTOPRIL, ENALAPRIL, AND LOSARTAN ON INFLAMMATORY MEDIATOR-INDUCED VEGF OVERPRODUCTION IN HMC
As we showed recently, the proinflammatory cytokines IL-1α and TNF-α are able to stimulate mesothelial production of VEGF (1 
EFFECTS OF CAPTOPRIL, ENALAPRIL, AND LOSARTAN ON INFLAMMATORY MEDIATOR-ENHANCED VEGF mRNA LEVELS
In accordance with the protein data, the HMC treatment with captopril 1000 µmol/L, enalapril 1000 µmol/L, and losartan 100 µmol/L resulted in a marked reductions in TNF-α-induced VEGF mRNA enhancement. Incubation times of 8 hours and 24 hours showed similar findings ( Figure 6 ).
The incubation with IL-1α (10 U/mL) also enhanced VEGF mRNA. This overexpression could clearly be diminished with captopril 1000 µmol/L, enalapr il 1000 µmol/L, or losartan 100 µmol/L treatment. Incubation times of 8 hours and 24 hours showed similar findings ( Figure 7 ).
DISCUSSION
Peritoneal dialysis is a viable alternative to hemodialysis but is often limited by complications such as ultrafiltration failure (11) . Long-term PD is associated with various morphologic changes of the peritoneal membrane, such as mesothelial denudation, interstitial fibrosis, neovascularization, and vascular alterations (12, 13) . Although the mechanisms leading to these alterations and to peritoneal membrane dysfunction are not completely understood, growth factors such as transforming growth factor (TGF), basic fibroblast growth factor, and VEGF are supposed to play an important role in these processes (14) . Human mesothelial cells, which form the innermost layer of the peritoneum, are a major source of the intraperitoneally produced VEGF that can be found in peritoneal effluents of PD patients (15) . Mesothelial expression can be demonstrated by immunostaining of peritoneal tissue (16) . Particularly, VEGF is responsible for augmented vascular permeability, vasodilatation, and neoangiogenesis (17) , which result in an increased vascular surface area with a high peritoneal solute transport rate that is associated with ultrafiltration failure in long-term PD patients (18) . VEGF is a 45 kDa heparin-binding glycoprotein. Five different isoforms arise from alternative splicing, with VEGF 165 as the most abundant (19) . It can be produced by a variety of human tissues, including vascular endothelial and smooth muscle cells, fibroblasts, and mesangial cells (20) . Recently, we were able to demonstrate that glycated albumin (a byproduct of high glucose concentrations in PD fluids), thrombin, and the proinflammatory cytokines TNF-α and IL-1α result in enhanced mesothelial VEGF production (1). Consequently, we have been looking for agents that might attenuate the VEGF synthesis in HMC and reduce the VEGF overproduction due to proinflammatory cytokines.
Duman et al. showed a preservation of peritoneal function and morphological criteria by systemic and local treatment with enalapril in a rat PD model using hypertonic dialysis solutions. This enalapril treatment was able to significantly inhibit the overexpression of TGF-β (5,6). Both lisinopril and the AT1-receptor blocker valsartan led to an attenuation of impaired ultrafiltration associated with hypertonic PD solutions in a rat model (21) . Systemically applied lisinopril was able to significantly reduce blood TGF-β levels and decrease significantly the grade of adhesion in a rat laparotomy model (22) . Noh et al. found a preventive function of intraperitoneally applied losartan on PD-induced omental TGF-β1, VEGF, and angiotensin II overexpression, as well as dialysate VEGF and angiotensin II levels, in a rat PD model (23) . The same group recently demonstrated that HMC express all components of a RAS and that angiotensin II-induced elevation of TGF-β1 and fibronectin could be dosedependently inhibited by captopril and losartan (7) . Accordingly, Kyuden et al. showed an ACE inhibitor and AT1-receptor blocker-related reduction in mesothelial TGF-β1 overproduction that was induced by high glucose levels. The effect could be augmented with a combination of ACE inhibitor and AT1-receptor blocker (24) . Since HMC show levels of ACE activity equal to endothelial cells (8), we tested the effect of captopril and enalapril on mesothelial VEGF production. And since mesothelial cells express the AT1 receptor, we also employed losartan. All three substances (captopril, enalapril, and losartan) were able to significantly decrease mesothelial overproduction of VEGF induced by TNF-α and IL-1α. These findings on protein levels could be reproduced on transcriptional level.
Furthermore, we were able to demonstrate that incubation of HMC with captopril resulted in a concentrationdependent attenuation of the basal VEGF antigen, which could not be shown for enalapril and losartan. To exclude toxic effects of high captopril concentrations, trypan blue staining and the MTT assay were performed with no reduction in cell viability. The differing effects seen with captopril may result in other captopril mechanisms than ACE inhibition: Recent investigations showed that captopril has, in addition to its potential as ACE-inhibiting agent, a direct effect on early phosphorylation events induced by insulin in BC3H-1 monocytes as it increases insulin-induced insulin-receptor substrate-1 and threonine kinase B phosphorylation (25) . Captopril has also been found to inhibit the translocation of the p-65 component of nuclear factor-kappaB to the nucleus, and probably thus reduces TNF-α-induced IL-1β in human monocytes in a dose-dependent order (26) . Further investigations will be necessary to clarify the mechanisms of the observed captopril actions on basal mesothelial VEGF production.
Summarizing our findings, we were able to demonstrate that inhibition of ACE or blockade of the AT1 receptor effectively inhibits the overproduction of VEGF by proinflammatory cytokines. These data confirm former hints that pharmaceutical manipulation of the local RAS may be successful in the reduction of long-term PD complications.
